Khalid Ibrahem Husein Al Ghodran*, Amina Ali Dessouki, Heba MA Abdelrazek, Dahlia Ibrahim Badran and Emad M Gad
Background: Diabetic nephropathy is a chronic main microvascular consequence of untreated hyperglycemia, affects a significant portion of the population. It's thought to be the main factor causing end-stage kidney disease. Proinflammatory cytokine TNF-α is involved in the development and course of disease in diabetic nephropathy. Aim: This study aimed at the detection the validity of using tumor necrosis factor-alpha as earlier and reliable biomarker for diabetic nephropathy.
Materials and methods: This study included 125 Egyptian subjects attending the out patients clinic of the Department of Internal Medicine, 10th of Ramadan City Health Insurance Hospital and divided as follow Group A: Control group which included 20 healthy subjects. Study groups: Included 105 patients divided into three sub-groups: group B: 20 patients with diabetic mellitus, group C: 65 patient’s diabetic nephropathy, group D: 20 diabetic nephropathy and other complications.
Results: Our study showed that the tumor necrosis factor-alpha was increased significantly in group B, C and D compared with control group, the high mean values were recorded in group D (713.7 ± 18.5) followed by group C (524.1 ± 56.4) and group B (281.0 ± 76.6) while the control group had the lowest value. At cut-off level ≥ 83.5, tumor necrosis factor-alpha had 96.7% sensitivity and 79.7% specificity for diagnosing diabetic nephropathy.
Conclusion: The study found that patients with DM and DM-CKD had considerably higher serum levels of TNF-α. This suggests that TNF-α may have a function in mediating changes in DN and may contribute to the progression of DM to DN.
Published Date: 2026-08-17; Received Date: 2024-11-18
